Aveo Pharmaceuticals Inc (AVEO) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Aveo Pharmaceuticals Inc

CIK: 1325879 Ticker: AVEO
Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2013
Feb. 28, 2014
Jun. 28, 2013
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2013    
Document Fiscal Year Focus 2013    
Document Fiscal Period Focus FY    
Trading Symbol AVEO    
Entity Registrant Name AVEO PHARMACEUTICALS INC    
Entity Central Index Key 0001325879    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Common Stock, Shares Outstanding   51,793,605  
Entity Public Float     $ 93,057,173

View differences made from one year to another to evaluate Aveo Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aveo Pharmaceuticals Inc.


Assess how Aveo Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aveo Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive (loss) Income
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (parenthetical)
(loss) Earnings Per Common Share
(loss) Earnings Per Common Share (tables)
Accrued Expenses
Accrued Expenses (detail)
Accrued Expenses (tables)
Assumptions Used In Black Scholes Pricing Model For New Grants (detail)
Available For Sale Securities (detail)
Basic And Diluted Earnings Per Share (detail)
Collaboration And License Agreements
Collaborations And License Agreements - Additional Information (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Common Stock And Warrants
Common Stock And Warrants - Additional Information (detail)
Company Net Deferred Tax Assets (detail)
Employee Benefit Plan
Employee Benefit Plan - Additional Information (detail)
Future Annual Minimum Lease Payments (detail)
Future Minimum Payments Under Loans Payable (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Legal Actions
Legal Actions -additional Information (detail)
Loans Payable
Loans Payable (tables)
Loans Payable - Additional Information (detail)
Marketable Securities In Unrealized Loss Position (detail)
Nature Of Business And Organization
Nature Of Business And Organization - Additional Information (detail)
Potentially Dilutive Securities Excluded From Calculation Of Diluted Net Loss Or Earnings Per Share (detail)
Property And Equipment
Property And Equipment (detail)
Property And Equipment (tables)
Property And Equipment - Additional Information (detail)
Quarterly Results (unaudited)
Quarterly Results (unaudited) (tables)
Reconciliation Of Expected Income Tax Benefit (detail)
Reconciliation Of Gross Uncertain Tax Positions (detail)
Restricted Stock Activity (detail)
Restructuring Activity Recorded In Operating Expenses And Accrued Expenses (detail)
Significant Accounting Policies
Significant Accounting Policies (policies)
Significant Accounting Policies (tables)
Significant Accounting Policies - Additional Information (detail)
Stock Based Compensation Expense For Equity-classified Awards (detail)
Stock Option Activity (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Strategic Restructuring
Strategic Restructuring (tables)
Strategic Restructuring - Additional Information (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Cash Equivalents And Marketable Securities Measured At Fair Value On Recurring Basis (detail)
Summary Of Quarterly Results (detail)
Ticker: AVEO
CIK: 1325879
Form Type: 10-K Annual Report
Accession Number: 0001193125-14-097636
Submitted to the SEC: Thu Mar 13 2014 4:00:05 PM EST
Accepted by the SEC: Thu Mar 13 2014
Period: Tuesday, December 31, 2013
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: